About 30% of depressive patients cannot be successfully treated with the initial treatment; it is called treatment-resistant depression (TRD).
Dr. Helge Müller, MD, Deputy Hospital Director of the Department of Psychiatry and Psychotherapy, coordinates the RESTORE-LIFE study in the University Hospital of Bonn, in partnership with LivaNova, Sponsor of the study.
RESTORE-LIFE is an international post-market observational study evaluating VNS-therapy® as adjunctive treatment and is designed to assess the short- and long-term effectiveness and efficiency of outcomes in TRD patients. Data are collected on their response to treatment, quality of life, productivity and health care utilization. The follow-up phase lasts 3-5 years.